CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DACARBAZINE	*USP Reference*	*USP36–NF31*	3137	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First*	Line 3 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR INJECTION	*standards <11>*						*Supplement to USP37–NF32*	Dacarbazine Related Compound B RS: Change $C_4H_3N_5O$ 137.10 to: $C_4H_3N_5O \cdot H_2O$ 155.12
EDETATE DISODIUM	ASSAY/ *Procedure*	*USP36–NF31*	3370	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 5: Delete *Titrimetric system* (See *Titrimetry* <541>.) *Mode*: Direct titration *Titrant*: 0.1 N sodium hydroxide VS *Endpoint detection*: Visual
LAMOTRIGINE TABLETS	PERFORMANCE TESTS/ *Dissolution* <711>/*Test 1*	*USP36–NF31*	4056	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Standard solution*: Change 0.028 µg/mL to: 0.028 mg/mL
TRAMADOL HYDROCHLORID	IMPUR	*USP36–NF31*	5438	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to*	Footnote c: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E EXTENDED-RELEASE TABLETS	ITIES/*Organic Impurities*/*Table 2*						*USP37–NF32*	1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). AND Footnote d: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
PURIFIED GYMNEMA EXTRACT	COMPOSITION /*Content of Gymnemic Acids*	*First Supplement to USP36–NF31*	5884	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change 90%–110% of the labeled amount to: 90.0%–110.0% of the labeled amount on the dried basis

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM HYDROXIDE	ASSAY/ *Procedure*	*USP36–NF31*	2203	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change = volume of *Titrant* consumed by the *Sample* to the first endpoint (mL) to: = volume of *Titrant* consumed by the *Sample* to the second endpoint (mL)
CLARITHROMYCIN FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3018	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Change the subsection head *Buffer*: to: *Buffer A*: AND After the *Buffer A* subsection: Add *Buffer B*: 0.067 M dibasic potassium phosphate AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Mobile phase*: Change Methanol and *Buffer* to: Methanol and *Buffer A* AND Line 4 of *Sample stock solution*: Change with the aid of 330 mL of *Buffer*, to a 1000-mL volumetric flask containing 50 mL of *Buffer*. to: with the aid of 330 mL of *Buffer B*, to a 1000-mL volumetric flask containing 50 mL of *Buffer B*.
PENTAZOCINE INJECTION	*Chemical Information*	*USP36–NF31*	4734	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Remove all chemical information.
POTASSIUM	*Assay*	*USP36–NF31*	4838	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE EX TENDED-RELEASE CAPSULES								*Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution.
SELEGILINE HYDROCHLORIDE TABLETS	*Dissolution <711>*	*USP36–NF31*	5120	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change Chromatograph the *Standard solution*, and record the peak responses. to: The flow rate is 1.0 mL/min. Chromatograph the *Standard solution*, and record the peak responses.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization General Principle* to: *Method 6—Precolumn DABS-Cl Derivatization*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	5558	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	*General Principle* Line 2 of *Mobile phase*: Change 0.01 M to: 0.01 N AND Line 7 of *Assay preparation*: Change 10-mL to: 100-mL
AMITRIPTYLINE HYDROCHLORIDE TABLETS	IDENTIFICATION/*A*.	*USP36–NF31*	2464	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample stock solution: Nominally 0.1 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate. *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride from *Sample stock solution* in methanol
MINOCYCLINE FOR INJECTION	*Assay*	*USP36–NF31*	4375	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system—Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer porosity. Make adjustments if necessary (see *System Suitability* under *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>). *Standard prep aration* —Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
OXYCODONE AND ACETAMINOPHEN TABLETS	IDENTIFICATION/*A. Thin-Layer Chromatography*	*USP36–NF31*	4645	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Sample solution*: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1).
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR	*Assay for potassium*	*USP36–NF31*	4834	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SOLUTION								*Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS	*Assay*	*USP36–NF31*	4841	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution* and *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparations—to: *Standard stock solution* and *Standard solutions*—Line 1 of *Procedure*: Change in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation 1* or *Assay preparation 2* instead of *Sample solution*.
ISOTRETINOIN CAPSULES	PERFORMANCE	*Revision Bulletin (Official*	Online	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Medium*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/ *Dissolution <711>/Test 4*	*October 01, 2012)*						Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of lauryl dimethyl amine oxide
TROLAMINE SALICYLATE	*Assay*	*USP36–NF31*	5499	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change L1 to: L7
NITRIC ACID	ASSAY/ *Procedure*	*USP36–NF31*	2107	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conical flask, and add 25 mL of water.
FOSPHENYTOIN SODIUM INJECTION	*Assay*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Assay preparation*: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium,
MOXIFLOXACIN OPHTHALMIC SOLUTION	*Assay*	*USP36–NF31*	4414	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of *Resolution solution*: Change 0.1 mg per mg and 0.001 mg per mg,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION	*Assay*	*USP36–NF31*	4833	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	to: 0.1 mg per mL and 0.001 mg per mL, Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solution, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE FOR ORAL SOLUTION	*Assay*	*USP36–NF31*	4840	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Potassium Chloride Oral Solution, except use *Assay preparation 1* or *Assay preparation 2* instead of *Sample solution*.
TACROLIMUS CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5257	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 11 of USP Tacrolimus System Suitability Mixture RS: Change and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-m

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21-(4*H*,23*H*)-tetrone. to: and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21-(4*H*,23*H*)-tetrone.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	APPENDIX	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization* to: *Method 6—Precolumn DABS-Cl Derivatization*
VITAMIN E	SPECIFIC TESTS/*Acidity*	*USP36–NF31*	5579	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample*: Change 40 mg to: 1.0 g
FOSPHENYTOIN SODIUM	*USP Reference standards <11>*	*USP36–NF31*	3679	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	4376	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	$C_{14}H_{13}NO_2$ Line 2: Change *Mobile phase* and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								record the chromatograms, and measure the responses for the major peaks.
OXYCODONE TEREPHTHALATE	ASSAY/ *Procedure*	*USP36–NF31*	4648	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 7 of *Analysis*: Change R_U = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Standard solution* R_S = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Sample solution* to: R_U = peak response ratio of oxycodone to ethylparaben

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Sample solution* R_S = peak response ratio of oxycodone to ethylparaben from the *Standard solution*
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES	*Dissolution <711>*	*USP36–NF31*	4838	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 7 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conditions and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*.
POTASSIUM CHLORIDE, POTASSIUM BI CARBONATE, AND POTASSIUM CITRATE EFFE RVESCENT TABLETS FOR ORAL SOLUTION	*Assay for potassium*	*USP36–NF31*	4843	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Potassium Chloride Oral Solution, except use *Assay preparation* instead of *Sample solution*.
ETHYLENE OXIDE AND DIOXANE	*Method II*	*USP36–NF31*	148	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 31 of *Analysis*: Change r_S = ethylene oxide peak responses from *Standard solution B* to: r_S = dioxane peak responses from *Standard solution B*
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP36–NF31*	5558	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Sodium acetate solution*: Change 0.01 M to: 0.01 N AND Line 6 of *Assay preparation*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ALBUTEROL SULFATE	*Chromatographic purity*	*USP36–NF31*	2352	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change 10-mL to: 100-mL Line 1: Change It meets the requirements of the test for *Chromatographic purity* under *Albuterol*, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the *Standard solution* and the *Test solution*. to: It meets the requirements of the test for *Organic Impurities* under *Albuterol*, except to read

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the *Standard solution* and the *Sample solution*.
MINOCYCLINE HYDROCHLORIDE CAPSULES	*Assay*	*USP36–NF31*	4375	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peaks.
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP36–NF31*	4509	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Solution A*: Change Dissolve 330.9 mg of sodium phosphate to: Dissolve 330.9 g of dibasic sodium phosphate
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION	*Assay for potassium*	*USP36–NF31*	4834	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solution. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS	*Dissolution <711>*	*USP36–NF31*	4841	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution*— to: *Standard stock solution*— AND Line 7: Change Prepare as directed for *Standard preparations* to: Prepare as directed for *Standard solutions*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 7 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*.
THIMEROSAL TOPICAL AEROSOL	SPECIFIC TESTS/*Alcohol Determination, Method II <611>*	*USP36–NF31*	5369	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of *Analysis*: Change Determine the alcohol content of the sample thus prepared by the *Gas–Liquid Chromatographic Method* (see *Method II* in *Alcohol Determination*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<611>, using methyl ethyl ketone as the internal standard in place of acetone. to: Determine the alcohol content of the sample thus prepared by the *Gas Chr omatographic Method* (see *Method II* in *Alcohol D ete rminat ion* <611>), using methyl ethyl ketone as the internal standard in place of acetonitrile.
CARAWAY OIL DEFINITION		*USP36–NF31*	1924	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3: Change It contains NMT 50.0% of *d* -carvone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{10}H_{14}O$). to: It contains NLT 50.0% of *d*-carvone ($C_{10}H_{14}O$).
NORTRIPTYLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*First Supplement to USP36–NF31*	6027	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Acceptance criteria*: Change *Standard solution* to: *Sample solution*
FOSPHENYTOIN SODIUM INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
MINOCYCLINE HYDROCHLORIDE TABLETS	*Assay*	*USP36–NF31*	4378	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak responses as directed for *Procedure*: the capacity factor, k', is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								record the chromatograms, and measure the responses for the major peaks.
HYDROGENATED POLYDECENE	ASSAY/*Content of Decene Oligomer*	*USP36–NF31*	2133	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *System suitability*: Change [Note—The retention time for squalene is about 18 min; the relative retention times for tetradecane, hexadecane, and squalene are about 0.5, 0.6, and 1.0, respectively.] to: [Note—The retention time for squalane is about 18 min; the relative retention times for tetradecane, hexadecane,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and squalane are about 0.5, 0.6, and 1.0, respectively.]
CLOTRIMAZOLE AND BETAMETHASONE DI PROPIONATE CREAM	ASSAY/*Procedure*	*USP36–NF31*	3075	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Betamethasone dipropionate stock solution*: Change *J* being the ratio (in mg/g) of betamethasone to clotrimazole in the Cream to: *J* being the ratio of the labeled amount of betamethasone (in mg/g) to the labeled amount of clotrimazole (in mg/g) in the Cream
CALCIUM SULFATE	SPECIFIC TESTS/*Loss on Drying <731>*	*USP35–NF30*	1724	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Acceptance criteria*: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate
TAPIOCA STARCH	*Limit of oxidizing substances*	*USP35–NF30*	1987	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 8: Change Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodide color. to: Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodine color.
LEVETIRACETAM	ADDITIONAL REQUIREMENT	*USP35–NF30*	3659	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 9 of *USP Reference*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S							*Standards <11>*: Change $C_8H_{14}ClNO_3$ 207.65 to: $C_8H_{15}ClN_2O_2$ 206.67
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*/ *Chromatographic system*	*Second Supplement to USP35–NF30*	5940	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Column*: Change 4.6-mm x 7.5-cm; 3-µm packing L7 to: 4.6-mm x 7.5-cm; 3- or 3.5-µm packing L7

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38